Effect of Hyperglycemia on Gastric Emptying Interactions With Pramlintide

Inclusion Criteria: All of the following criteria are to be fulfilled for inclusion of an individual in the study unless the investigator grants an exception: * Clinical diagnosis of type 1 diabetes (otherwise healthy) with an HbA1 ≤ 9%, and on a stable insulin treatment for at least 3 months (preferably on pump regimen) prior to screening OR is a healthy individual. * 20-40 years of age, inclusive. * Understand and sign an informed consent document, communicate with the investigator, and understand and comply with the requirements of the study. * Euthyroid, including subjects receiving thyroid replacement therapy. If female: * Is surgically sterilized by hysterectomy; OR * Is post-menopausal, as documented by a history of amenorrhea for 6 months and follicle stimulating hormone (FSH) level within the range specified as post-menopausal by the reporting laboratory at screen (post menopausal women on estrogen may enter the study without obtaining an FSH level); OR * If of childbearing potential, meets the following criteria: negative pregnancy test (ß-HCG), regardless of birth control method (including subjects with tubal ligation); * Practicing and willing to continue throughout the study the appropriate contraception (defined as oral, injected, or implanted contraceptives for at least 3 months prior to entry, or barrier contraception). * Agree to take every precaution to ensure that pregnancy will not occur during the study. Exclusion Criteria: * Individuals meeting any of the following criteria are to be excluded from the study unless the investigator grants an exception: * History of severe hypoglycemia. * Body mass index (BMI) ≥ 30 kg/m2. * Autonomic nerve dysfunction: abnormal result in the cardiovascular parasympathetic and/or sympathetic tests (screening visit). Hepatic disease: * Known hepatic disease or transaminases (GOT, GPT) ≥ 2x above normal values. Renal disease: * Known or serum urea, serum creatinine ≥ 1.5x above normal values * Cardiovascular or pulmonary disease: * Arterial hypertension * Blood pressure \>150/95 mmHg at screening in a sitting position) * Arterial occlusive disease * Known coronary heart disease * Abnormal ECG at screening visit. * Gastrointestinal disease: * Any known structural gastrointestinal disorder, * Gastrointestinal surgery except for appendectomy, * Symptoms indicating functional or structural upper gastrointestinal disorder (pain, bloating, postprandial fullness, nausea, emesis, * Gastroectomy, gastroparesis, lactose intolerance, and diseases known to alter small bowel absorption; e.g., inflammatory bowel disease. CNS disease: * Epilepsy (including subjects with a past history of convulsions associated with hypoglycaemia), * Psychiatric illness (including history of eating disorder such as bulimia or anorexia). * Autoimmune disease other than thyroid, pernicious anemia, or vitiligo. * Malignant disease requiring chemotherapy, * Any acute febrile illness within 2 weeks of Screening (Visit 1) with a temperature of 100°F, * Currently abusing alcohol or drugs, or have a history of alcohol or drug abuse that in the investigator's opinion could cause the subject to be non-compliant; or have a general history of non-compliance with medications. * Receipt of any investigational drug within 90 days of Screening (Visit 1) (prior treatment with pramlintide is permissible). * Currently treated with medications known to interfere with gastric emptying such as, but not limited to: * Ca2+ channel antagonists, ß-receptor antagonists, prokinetic agents metoclopramide (Reglan®) and cisapride (Propulsid®); and * Chronic (more than 10 days within a 6-month period) macrolide antibiotics such as erythromycin and newer derivatives. * Currently treated with: * Bile acid sequestering resins cholestyramine (Questran®) and colestipol (Colestid®), * Systemic steroids, * Anti-obesity agents (including orlistat \[Xenical®\] and sibutramine \[Meridia®\]), * Alpha-glucosidase inhibitors (acarbose \[Precose®\] and miglitol \[Glyset®\]) and meglitinides (\[Prandin®\] and \[Starlix®\]).